ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II

NCT ID: NCT01740895

Last Updated: 2014-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

818 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the clinical value of iFR to characterize, without concomitant administration of hyperemic agents and outside a specified range of iFR values, coronary stenosis severity as determined with fractional flow reserve (FFR)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Patient must be \> 18 and \< 85 years of age
* Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
* Eligible for coronary angiography and/or percutaneous coronary intervention
* Coronary artery disease with at least 1 or more visually assessed coronary stenoses (\>40% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram.
* Stable angina or acute coronary syndromes (non-culprit vessels only and outside of primary intervention during acute myocardial infarction)

Exclusion Criteria

* \- Known contraindication to adenosine administration
* Implanted temporary or permanent artificial pacemakers, Left Bundle Branch Block (LBBB), 1st and 2nd degree AV Block
* STEMI or non STEMI within 48 hours of procedure
* Any contraindications for FFR interrogation or percutaneous coronary intervention (PCI) as determined by the investigator
* Severe vessel tortuosity and/or severe calcification by angiogram
* Significant valvular pathology (moderate or severe AS/AR/MS/MR)
* Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel
* Weight \>200kg (441 lbs.)
* Hemodynamic instability at the time of intervention (heart rate\<50 beats per minute, systolic blood pressure \<90mmHg) balloon pump
* Significant hepatic disease, renal disease, lung disease (pulmonary chronic pulmonary obstructive disease) and/or malignant disease with unfavorable prognosis or presenting with abnormal serum laboratory values that the physician believes is clinically significant
* Contraindication to antithrombotic regimen or anticoagulation therapy
* History of or known reaction or sensitivity to contrast agent and is unable to be pre-medicated
* Left main stenosis, tandem stenosis separated by more than 5 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis), or total occlusions
* Known Left ventricular ejection fraction (LVEF) \<30%
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Volcano Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javier Escaned, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Cl¡nico San Carlos Madrid Spain

Amir Lerman, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic Rochester MN USA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chandler Regional Medical Center

Chandler, Arizona, United States

Site Status

Mercy Gilbert Medical Center

Gilbert, Arizona, United States

Site Status

Coloado Heart and Vascular/St Anthony's

Lakewood, Colorado, United States

Site Status

Cardiovascular Research of Florida

Gainesville, Florida, United States

Site Status

North Florida regional Medical center

Gainsville, Florida, United States

Site Status

Baptist Cardiac & Vascular Institute

Miami, Florida, United States

Site Status

Winter Haven Hospital

Winter Haven, Florida, United States

Site Status

St Johns Hospital/ Prairie Education and Research

Springfield, Illinois, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

St. Marys Hospital/ MAYO Clinic

Rochester, Minnesota, United States

Site Status

Regions Hospital Heart Center

Saint Paul, Minnesota, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

AtlantiCare Regional Medical Center

Pomona, New Jersey, United States

Site Status

Stony Brook Medicine

Stony Brook, New York, United States

Site Status

University of North Carolina Hospital

Chapel Hill, North Carolina, United States

Site Status

Duke University Hospital

Durham, North Carolina, United States

Site Status

East Carolina University/ Pitt County Hospital

Greenville, North Carolina, United States

Site Status

Wake Heart research/ Rex Hospital

Raleigh, North Carolina, United States

Site Status

Wake Heart research/ Wake Medical Center

Raleigh, North Carolina, United States

Site Status

Forsyth Medical Center

Winston-Salem, North Carolina, United States

Site Status

Geisinger Medical Center

Danville, Pennsylvania, United States

Site Status

UPMC Hamot

Erie, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Allegheny General

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

VA Charleston (RALPH H. JOHNSON VA MEDICAL CENTER)

Charleston, South Carolina, United States

Site Status

Greenville Memorial Hospital

Greenville, South Carolina, United States

Site Status

Wellmont Holston Valley Medical center

Kingsport, Tennessee, United States

Site Status

Sentara Health/Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Auora St Lukes

Milwaukee, Wisconsin, United States

Site Status

Victoria Heart Institute Foundation

Victoria, British Columbia, Canada

Site Status

Al Dorrah

Cairo, , Egypt

Site Status

Kerckhoff Klinik Bad Nauheim

Bad Nauheim, , Germany

Site Status

AMC Amsterdam

Amsterdam, , Netherlands

Site Status

Breda Amphia Ziekenhuis

Breda, , Netherlands

Site Status

Medische Spectrum Twente

Enschede, , Netherlands

Site Status

ERASMUS MC Rotterdam

Rotterdam, , Netherlands

Site Status

Jagiellonian University, Institute of Cardiology

Krakow, , Poland

Site Status

MSWiA Warszawa Woloska

Warsaw, , Poland

Site Status

Polikliniką SP ZOZ we Wrocławiu

Wroclaw, , Poland

Site Status

Hospital Universitario San Juan

Alicante, , Spain

Site Status

Hospital Universitario La Paz de Madrid

Madrid, , Spain

Site Status

Hospital Cl¡nico San Carlos

Marid, , Spain

Site Status

Liverpool Heart and Chest Hospital

Liverpool, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Egypt Germany Netherlands Poland Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Echavarria-Pinto M, van de Hoef TP, Garcia-Garcia HM, de Vries T, Serruys PW, Samady H, Piek JJ, Lerman A, Escaned J; ADVISE II Study Group. Diagnostic Accuracy of Baseline Distal-to-Aortic Pressure Ratio to Assess Coronary Stenosis Severity: A Post-Hoc Analysis of the ADVISE II Study. JACC Cardiovasc Interv. 2015 May;8(6):834-836. doi: 10.1016/j.jcin.2014.12.245. No abstract available.

Reference Type DERIVED
PMID: 25999107 (View on PubMed)

Escaned J, Echavarria-Pinto M, Garcia-Garcia HM, van de Hoef TP, de Vries T, Kaul P, Raveendran G, Altman JD, Kurz HI, Brechtken J, Tulli M, Von Birgelen C, Schneider JE, Khashaba AA, Jeremias A, Baucum J, Moreno R, Meuwissen M, Mishkel G, van Geuns RJ, Levite H, Lopez-Palop R, Mayhew M, Serruys PW, Samady H, Piek JJ, Lerman A; ADVISE II Study Group. Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance: Results of ADVISE II International, Multicenter Study (ADenosine Vasodilator Independent Stenosis Evaluation II). JACC Cardiovasc Interv. 2015 May;8(6):824-833. doi: 10.1016/j.jcin.2015.01.029.

Reference Type DERIVED
PMID: 25999106 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PFC-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.